SRSF2 and myelodysplastic syndrome: Due to the prevalence of mutations in spliceosomal proteins, such as DDX41, SF3B1, U2AF1, or SRSF2 in AML/MDS patients, it is tempting to speculate that DHX34 mutations and/or alternative splicing changes found in these patients could compromise not only its function in NMD, but also affect splicing events mediated by DHX34.